Table 2.
Summary of Tafenoquine and Moxifloxacin Plasma Pharmacokinetic Parameters
| AUC(0–t) | AUC(0–∞) | Cmax | tlast | tmax | t1/2 | ||
|---|---|---|---|---|---|---|---|
| Group | N | (ng mL–1 h) | (ng mL–1 h) | (ng/mL) | (h) | (h) | (h) |
| TQ 300 mg | 51 | 10611 (29.7) | N/C | 186 (31.3) | 72.0 (71.9–73.0) | 15.0 (9.0–48.2) | N/C |
| TQ 600 mg | 52 | 22986 (29.6) | N/C | 422 (32.4) | 72.0 (72.0–73.0) | 12.0 (5.0–36.4) | N/C |
| TQ 1200 mg | 51 | 41896 (26.0) | N/C | 724 (24.7) | 72.0 (72.0–73.0) | 12.0 (3.0–48.1) | N/C |
| Moxifloxacin 400 mg | 52 | 22554 (23.3) | 23778 (23.1) | 1554 (27.8) | 72.0 (48.0–72.0) | 3.0 (1.0–6.3) | 16.1 (10.0–22.8) |
AUC(0–t), AUC(0–∞), and Cmax are the geometric mean (% CVb). tlast, tmax, and t1/2 are the median (range). AUC, area under the concentration–time curve; CVb, between-subject coefficient of variance; Cmax, maximum observed concentration; N/C, not calculated; tlast, time of last quantifiable concentration; t1/2, terminal phase half life; tmax, time of maximum plasma concentration; TQ, tafenoquine.